Matthew K. Fust - 20 Mar 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Director
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
20 Mar 2024
Net transactions value
-$1,393,175
Form type
4
Filing time
22 Mar 2024, 16:31:10 UTC
Previous filing
11 Mar 2024
Next filing
02 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $290,500 +12,500 +67% $23.24 31,036 20 Mar 2024 Direct
transaction CRNX Common Stock Sale $544,625 -12,500 -40% $43.57 18,536 20 Mar 2024 Direct F1, F2
transaction CRNX Common Stock Options Exercise $290,375 +12,500 +67% $23.23 31,036 20 Mar 2024 Direct
transaction CRNX Common Stock Sale $544,625 -12,500 -40% $43.57 18,536 20 Mar 2024 Direct F1, F2
transaction CRNX Common Stock Options Exercise $354,025 +17,500 +94% $20.23 36,036 20 Mar 2024 Direct
transaction CRNX Common Stock Sale $762,650 -17,500 -49% $43.58 18,536 20 Mar 2024 Direct F1, F3
transaction CRNX Common Stock Options Exercise $320,075 +17,500 +94% $18.29* 36,036 20 Mar 2024 Direct
transaction CRNX Common Stock Sale $796,250 -17,500 -49% $45.50 18,536 20 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (right to buy) Options Exercise $0 +12,500 $0.000000* 0 20 Mar 2024 Common Stock 12,500 $23.24 Direct F4
transaction CRNX Stock Option (right to buy) Options Exercise $0 +12,500 $0.000000* 0 20 Mar 2024 Common Stock 12,500 $23.23 Direct F4
transaction CRNX Stock Option (right to buy) Options Exercise $0 +17,500 $0.000000* 0 20 Mar 2024 Common Stock 17,500 $20.23 Direct F4
transaction CRNX Stock Option (right to buy) Options Exercise $0 +17,500 $0.000000* 0 20 Mar 2024 Common Stock 17,500 $18.29 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.57 per share. The range of sales prices on the transaction date was $42.70 to $44.23 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F3 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.58 per share. The range of sales prices on the transaction date was $42.70 to $44.23 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F4 The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.